UHealth - University of Miami Health System

Luca A. Inverardi, M.D.

General Information

Luca A. Inverardi, M.D.

Languages

  • English
  • Italian, American

Roles

  • Co-Director, Cell Transplant Center, Diabetes Research Institute
  • Deputy Director Diabetes Research Institute
  • Research Professor of Medicine, Microbiology and Immunology

Clinical Interests

 Define options and opportunities to move to clinical trials for the treatment of type 1 DM

Research Interests

Immunobiology of islet transplantation, cytoprotection for the improvement of islet engraftment, immunological tolerance induction, xenotransplantation, beta cell biology and signal transduction, pancreas developmental biology

Education

1983 M.D.
State University of Milano School of Medicine
Undergraduate
Classic Lycaeum Parini
Graduate
State University of Milano School of Medicine
Residency
State University of Milano School of Medicine
Fellowship
Immunobiology Research Center University of Minnesota

Publications

  • More Publications
  • Concise review: clinical programs of stem cell therapies for liver and pancreas. Lanzoni G, Oikawa T, Wang Y, Cui CB, Carpino G, Cardinale V, Gerber D, Gabriel M, Dominguez-Bendala J, Furth ME, Gaudio E, Alvaro D, Inverardi L, Reid LM. Stem Cells. 2013 Oct;31(10):2047-60. doi: 10.1002/stem.1457. Review.
  • Influence of in vitro and in vivo oxygen modulation on ß cell differentiation from human embryonic stem cells. Cechin S, Alvarez-Cubela S, Giraldo JA, Molano RD, Villate S, Ricordi C, Pileggi A, Inverardi L, Fraker CA, Domínguez-Bendala J. Stem Cells Transl Med. 2014 Mar;3(3):277-89. doi: 10.5966/sctm.2013-0160. Epub 2013 Dec 27.
  • Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Zoso A, Mazza EM, Bicciato S, Mandruzzato S, Bronte V, Serafini P, Inverardi L. Eur J Immunol. 2014 Nov;44(11):3307-19. doi: 10.1002/eji.201444522. Epub 2014 Oct 18.
  • Improved human islet preparations using glucocorticoid and exendin-4. Miki A, Ricordi C, Yamamoto T, Sakuma Y, Misawa R, Mita A, Inverardi L, Alejandro R, Ichii H. Pancreas. 2014 Nov;43(8):1317-22. doi: 10.
  • Biliary tree stem cells, precursors to pancreatic committed progenitors: evidence for possible life-long pancreatic organogenesis. Wang Y, Lanzoni G, Carpino G, Cui CB, Dominguez-Bendala J, Wauthier E, Cardinale V, Oikawa T, Pileggi A, Gerber D, Furth ME, Alvaro D, Gaudio E, Inverardi L, Reid LM. Stem Cells. 2013 Sep;31(9):1966-79.
  • MicroRNA expression in alpha and beta cells of human pancreatic islets. Klein D, Misawa R, Bravo-Egana V, Vargas N, Rosero S, Piroso J, Ichii H, Umland O, Zhijie J, Tsinoremas N, Ricordi C, Inverardi L, Domínguez-Bendala J, Pastori RL. PLoS One. 2013;8(1):e55064.
  • From cellular therapies to tissue reprogramming and regenerative strategies in the treatment of diabetes. Ricordi C, Inverardi L, Domínguez-Bendala J. Regen Med. 2012 Nov;7(6 Suppl):41-8. doi: 10.2217/rme.12.70. Review.
  • Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice. Dong H, Fahmy TM, Metcalfe SM, Morton SL, Dong X, Inverardi L, Adams DB, Gao W, Wang H. PLoS One. 2012;7(12):e50265. doi: 10.1371/journal.pone.0050265.
  • Concise review: mesenchymal stem cells for diabetes. Domínguez-Bendala J, Lanzoni G, Inverardi L, Ricordi C. Stem Cells Transl Med. 2012 Jan;1(1):59-63. doi: 10.5966/sctm.2011-0017. Epub 2011 Dec 7. Review.

Biography

 

Luca Inverardi received his M.D. degree in Milan, Italy, on Jan 30 1985.  His research has always been focused on improving the quality of life of patients with T1DM.  20 years ago he was offered a position at the DRI (UM) and has been working here ever since, fully focused on finding a cure for T1DM. 
More than 44 patients with T1DM have received islet transplantation at the DRI and have clearly shown that  allogeneic islets can substantially improve health in T1DM recipients.
On the other hand, there are many issues that steel need to be addressed and resolved, including the fact that islet transplant recipients need to receive powerful immunosuppressive drugs that, in some instances, may have unwanted side effects.  Hence, we are focused on the definition of safe and efficient treatments that will allow to increase the survival rate of allogeneic islets, while decreasing the need for immunosuppressive drug delivery.